Skip to main content
. 2020 May 9;23(5):e25456. doi: 10.1002/jia2.25456

Table 1.

Maternal, household and child baseline characteristics among CHEU and CHU

Baseline characteristica CHEU CHU p value
Mothers [N] 216 1195  
Children [N] 219 1206  
Trial arm
SOC 68/219 (31.1%) 387/1206 (32.1%) 0.77
IYCF 68/219 (31.1%) 398/1206 (33.0%)  
WASH 83/219 (37.9%) 421/1206 (34.9%)  
Maternal characteristics
Mean age (SD), years 30.7 (6.3) 26.4 (6.6) <0.0001
Mean height (SD), cm 160.6 (6.5) 160.3 (6.0) 0.50
Mean MUAC (SD), cm 26.5 (3.2) 26.5 (3.2) 0.92
Mean completed schooling (SD), years 9.1 (2.1) 9.6 (1.8) 0.0008
Median parity (IQR) 2.5 (2, 3) 2 (1, 3) <0.0001
Married 191/200 (95.5%) 1073/1125 (95.4%) 0.94
Employed 18/208 (8.7%) 107/1110 (9.6%) 0.66
Religion
Apostolic 100/216 (46.3%) 555/1195 (46.4%) 0.057
Other Christian religions 80/216 (37.0%) 509/1195 (42.6%)  
Other non‐Christian religions 36/216 (16.7%) 131/1195 (11.0%)  
Maternal capabilitiesb
Mean gender norms and attitudes score (SD) 2.32 (0.82) 2.30 (0.82) 0.94
Mean perceived social support score (SD) 3.54 (0.64) 3.61 (0.58) 0.15
Mean perceived physical health (SD) 3.54 (1.00) 3.42 (1.00) 0.14
Mean mothering self‐efficacy score (SD) 4.05 (0.37) 3.98 (0.40) 0.020
Mean perceived time stress score (SD) 2.82 (0.75) 2.64 (0.70) 0.012
Median decision‐making autonomy (IQR) 5 (4,5) 5 (4,5) 0.78
Mean Edinburgh postnatal depression score (SD) 3.31 (4.59) 2.47 (3.78) 0.006
HIV disease severity and treatment
Mean CD4 count in pregnancy (SD), cells/μLc 456 (210) N/A  
Documented antiretroviral therapy during pregnancyd 185/216 (85.7%) N/A  
Tenofovir disoproxil fumarate‐based ART regimen 134/185 (72.4%) N/A  
Zidovudine‐based ART regimen 29/185 (15.7%) N/A  
Other/unknown ART regimene 22/185 (11.9%) N/A  
Documented co‐trimoxazole prophylaxis during pregnancyf 137/216 (63.4%) N/A  
Household characteristics
Median household size (IQR) 4 (3, 6) 5 (3, 6) 0.32
Median coping strategies index score (IQR)g 2 (0, 11) 1 (0, 8) 0.006
Wealth quintileh
Lowest 50/209 (23.9%) 193/1115 (17.3%) 0.091
Second 43/209 (20.6%) 218/1115 (19.6%)  
Middle 45/209 (21.5%) 233/1115 (20.9%)  
Fourth 36/209 (17.2%) 244/1115 (21.9%)  
Highest 35/209 (16.8%) 227/1115 (20.4%)  
Child characteristics
Female 105/219 (48.0%) 609/1206 (50.5%) 0.48
Mean birth weight (SD), kg 3.00 (0.49) 3.09 (0.47) 0.057
Birth weight <2500 g 24/219 (11.4%) 100/1117 (8.7%) 0.39
Institutional delivery 183/212 (86.3%) 1015/1139 (89.1%) 0.23
Vaginal delivery 198/214 (92.8%) 1086/1169 (92.9%) 0.84

CHEU, children HIV‐exposed but uninfected; CHU, children HIV‐unexposed; IQR, interquartile range; IYCF, Infant and Young Child Feeding; MUAC, Mid‐upper arm circumference; SD, standard deviation; SOC, Standard of Care; WASH, Water and Sanitation/Hygiene.

a

Baseline variables presented for mothers who had live births. Maternal and household data were collected about two weeks after consent (approximately 14 weeks gestation); this gap created opportunity for loss to follow‐up between consent and baseline, thus the number of mothers completing baseline visit is smaller than the number of mothers with live births. Baseline for infants was at birth. Values are %, unless noted. For variables where [n] is not stated, <3% of data are missing based on number of baseline visits completed

b

maternal capabilities scores are described in Matare et al. 15 whereby scores generated for each of the caregiver capabilities measure, higher values represent greater decision‐making autonomy, more liberal gender norm attitudes, higher levels of depressive symptoms, greater mothering self‐efficacy, perceptions of better physical health, perceptions of more social support and perceptions of high levels of time stress

c

CD4 count at baseline visit, or at 32 gestational week visit if no baseline result

d

documented antiretroviral therapy use during pregnancy; only available for 187/216 (85.7%) women;

e

includes non‐TDF‐ or AZT‐based regimens; use of both TDF and AZT during pregnancy (including switching regimens); or undocumented antiretroviral therapy regimen

f

documented co‐trimoxazole prophylaxis use during pregnancy; only available for 134/216 (63.4%) women

g

the Coping Strategy Index is a measure of household food security (CARE and World Food Program, 2003).

h

described in Chasekwa et al. 14.